Navigation Links
Sysmex America Set to Launch New XT-Series(TM) Parameters
Date:10/30/2008

FDA-Cleared Parameters Aid in the Diagnosis of Infectious and Inflammatory

Diseases and in Monitoring Iron Deficiency

MUNDELEIN, Ill., Oct. 30 /PRNewswire/ -- Sysmex America, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared Sysmex's Immature Granulocyte (IG) parameter and Reticulocyte Hemoglobin Equivalent (RET-He) parameter for use on the company's XT-Series(TM) Automated Hematology Analyzers for low to mid-volume laboratories, said John Kershaw, President, Sysmex America, Inc. This announcement follows the company's earlier clearances of the same parameters for the Sysmex XE-Series(TM) Automated Hematology Analyzers. Now, clinical laboratories of any size can potentially benefit from enhanced diagnostic information, workflow process improvement, and greater cost-effectiveness, added Kershaw. The IG parameter is now available on both the XT-2000i and the XT-1800i, and the RET-He is available on the XT-2000i Automated Hematology Analyzers. Sysmex is the only company able to provide both of these FDA-cleared parameters.

"As a partner to clinical laboratories nationwide, Sysmex is committed to expanding the clinical utility of our hematology product line. These FDA clearances demonstrate our company's dedication to best-in-class hematology products and empowers clinical laboratories to improve their operations while enhancing patient care," said Kershaw.

About Immature Granulocytes and the Sysmex IG Parameter

The identification of immature granulocytes is primarily of importance in the diagnosis of infectious and inflammatory diseases. The IG parameter on the Sysmex XT-Series Automated Hematology Analyzers provides a quantitative immature granulocyte count for metamyelocytes, myelocytes and promyelocytes by utilizing Sysmex's patented fluorescent flow cytometry technology. This patented technology, used to separate white blood cells into distinct cell clusters, reduces labor-intensive manual WBC differential procedures, and improves turnaround time for results critical to patient care. Prior to Sysmex's automated immature granulocyte counting, manual differential counting of immature granulocytes was slow, expensive and imprecise.

About Reticulocytes and the Sysmex RET-He Parameter

The RET-He parameter is a sensitive measurement of iron available for red cell production. Functional iron available for incorporation into the red cell hemoglobin can be monitored via the RET-He, thus assisting physicians monitoring disease states where iron deficiency is often seen. Less than normal hemoglobin content in reticulocytes, immature red blood cells (RBCs), is an indication of inadequate iron supply relative to demand. The amount of hemoglobin in these reticulocytes also corresponds to the amount of hemoglobin in mature RBCs. The RET-He parameter provides a direct measurement of the mean reticulocyte hemoglobin content. Therefore, it is a useful parameter for assisting physicians with early diagnosis of iron deficiency (iron restricted erythropoiesis), and for optimizing iron therapy.

About Sysmex America, Inc.

Sysmex America, Inc., the U.S. headquarters of Sysmex Corporation (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation and information systems. Serving customers for over 40 years, Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide. For more information about Sysmex, please visit http://www.sysmex.com/usa.


'/>"/>
SOURCE Sysmex America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sysmex Announces Clinical Laboratory Software Name Change
2. Sysmex America Awarded MedAssets Supply Chain Systems Hematology Contract Extension
3. One of Nations Oldest Blood Services Providers Turns to Sysmex America
4. American Oriental Bioengineering, Inc. to Report Third Quarter 2008 Financial Results
5. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
6. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
7. CPC of America Announces Agreement with BC Tech for Manufacture of MedClose(TM) Vascular Closure System
8. Stenum Hospital Does its 600th American Disc Replacement Surgery
9. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
10. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
11. Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  Renova™ Therapeutics, a biotechnology company ... and type 2 diabetes, announced that it has ... virus (AAV) vector developed in the laboratory of ... Stanford University. The company plans to use this ... product pipeline. "Early research has ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard ...
(Date:12/8/2016)... 8, 2016  Anaconda BioMed S.L., a pre-clinical stage ... next generation neuro-thrombectomy system for the treatment of Acute ... Jovin, MD to join its Scientific Advisory Board (SAB). ... network of scientific and clinical experts to Anaconda BioMed ... ANCD BRAIN ® to its clinical phase. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...
Breaking Biology Technology:
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016  Zimmer Biomet ... that it has priced an offering of €500.0 million principal ... €500.0 million principal amount of its 2.425% senior unsecured notes ... is expected to occur on December 13, 2016, subject to the ... on an annual basis. ...
(Date:12/2/2016)... Texas , Dec. 1, 2016   ... today announced BioLock , an electrocardiogram (ECG) ... health monitoring, a key IoT asset. The smart ... into a vehicle,s steering wheel and mobile devices ... simple touch. As vehicle technology advances, ...
Breaking Biology News(10 mins):